Mostrar el registro sencillo del ítem
dc.contributor.author | Lingvay, Ildiko | |
dc.contributor.author | Harris, Stewart | |
dc.contributor.author | Jaeckel, Elmar | |
dc.contributor.author | Chandarana, Keval | |
dc.contributor.author | Ranthe, Mattis F. | |
dc.contributor.author | Jódar Gimeno, José Esteban | |
dc.date.accessioned | 2018-04-05T12:24:14Z | |
dc.date.available | 2018-04-05T12:24:14Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Lingvay, I., Harris, S., Jaeckel, E., Chandarana, K., Ranthe, M. F., & Jódar, E. (2018). Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes, Obesity and Metabolism, 20(1), 200-205. DOI: 10.1111/dom.13043 | spa |
dc.identifier.issn | 1462-8902 | |
dc.identifier.issn | 1463-1326 | |
dc.identifier.uri | http://hdl.handle.net/11268/7181 | |
dc.description.abstract | This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35 kg/m2 ) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial | spa |
dc.type | article | spa |
dc.description.impact | 6.133 JCR (2018) Q1, 16/145 Endocrinology & Metabolism | spa |
dc.description.impact | 2.777 SJR (2018) Q1, 9/137 Endocrinology, 11/245 Endocrinology, Diabetes and Metabolism, 8/141 Internal Medicine | spa |
dc.description.impact | No data IDR 2018 | spa |
dc.identifier.doi | 10.1111/dom.13043 | |
dc.rights.accessRights | openAccess | spa |
dc.subject.uem | Diabetes tipo 2 | spa |
dc.subject.uem | Insulina | spa |
dc.subject.unesco | Sistema endocrino | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.description.filiation | UEM | spa |
dc.relation.publisherversion | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763397/ | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |